Súil Delgado-Collins | Associate Principal
CRA, Charles River Associates
Súil is a consultant in in the Life Sciences Practice of CRA, with over seven years of experience supporting global pharmaceutical companies in strategic decision making across all stages of product development. Súil has worked across a range of project types and therapy areas, with emphasis in neurology and rare disease. She has an especially keen interest in projects exploring neurodegenerative disease, following her PhD research in the University of Cambridge, investigating the development of therapies for amyloidogenic disease. Súil established an ongoing pro-bono project with the European Coalition for Newborn Screening (ECNS), to support with the development of their position paper on the need for more equitable newborn screening in Europe
Appearances:
Day 1 - Tuesday 28 October @ 11:30
Working Group 2: Every Newborn Counts: The Quest for Equitable Newborn Screening in Europe
Over the past decade, newborn screening programs throughout Europe have seen significant advancements, both in the number of countries adopting them and the variety of disorders they screen for. Despite this progress, considerable disparities remain between countries, with the number of screened conditions varying widely. This session will explore the reasons behind these inequalities and discuss the advantages of achieving more equitable access to newborn screening across Europe for both patients and society.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events